Official Website: Thera-T Pharmaceutics
source confidence: Medium status: Useful updated 2026-08-11
Summary
Thera-T Pharmaceutics' official homepage describes its MATCH (Multi-Antigen T-Cell Hybridizers) platform for B-cell leukemias, lymphomas, and multiple myeloma, AI/ML-guided dosing models, three listed published works, and leadership including Thomas Gambles as president and co-founder and Jindřich Kopeček as co-founder and scientific advisor.
Useful Claims
- Thera-T describes MATCH as a multi-antigen T-cell-engager platform targeting B-cell leukemias, lymphomas, and multiple myeloma.
- The company says its platform can produce combinations of bispecific antibody-binding fragments and is developing AI/ML models for personalized bispecific immunotherapeutics.
- The site identifies Thomas Gambles as president and co-founder and Jindřich Kopeček as co-founder and scientific advisor.
- The capture lists three published works, but not the Advanced Healthcare Materials title previously asserted.
- Viral-manufacturing, University of Utah laboratory and accelerator ties, funding, animal studies, and the 2025 award do not appear in this capture and require separate sources.
Verbatim
"Customizable multi-specific antibody technology for cancer immunotherapy guided by predictive dose modeling and machine learning." — Home page, heading
"MATCH provides a platform targeting system capable of treating B-cell leukemias, lymphomas, and multiple myeloma through multi-specific targeting." — Home page, platform description
"MATCH is a platform capable of producing any bispecific combination of antibody binding fragments." — Home page, screening description
"Thera-T is developing theranostic AI/ML models to usher in a new era of personalized bispecific immunotherapeutics." — Home page, predictive modeling
"Multi-Antigen T-Cell Hybridizers: A Two-Component T-Cell-Activating Therapy" — Home page, published works
Reliability Notes
The official website is self-reported. The Advanced Healthcare Materials publication and TechBuzz profile provide independent corroboration of the mechanism and company existence. The University of Utah award is an institutional third-party validation. Funding figures ($400K) and animal study status reflect the intake period and should be verified from current sources. The AI-guided dosing model is described in company materials but has limited independent corroboration at this stage.
The 2026-08-11 capture does not contain the prior manufacturing, university-incubation, funding, animal-study, award, or Advanced Healthcare Materials claims. They are now explicitly treated as needing separate evidence.